Advertisement

Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis

Published:October 07, 2021DOI:https://doi.org/10.1016/j.amjmed.2021.08.026

      Abstract

      Background

      Patients with atrial fibrillation and bioprosthetic valves are at high risk for thromboembolic events. The pooled efficacy and safety of non-vitamin K oral anticoagulants (NOACs), as a class, relative to warfarin in this population is not well-known. We aimed to compare the efficacy and safety of NOACs relative to warfarin in patients with bioprosthetic valves or valve repair.

      Methods

      We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials comparing NOACs to warfarin in patients with atrial fibrillation and bioprosthetic valves or valve repair. We pooled outcomes for stroke or systemic embolism, ischemic stroke, hemorrhagic stroke, and major bleeding.

      Results

      We included 4 trials with 1379 patients, of whom 723 (52.4%) received a NOAC. Mean follow-up ranged from 90 days to 2.8 years. In the pooled analysis, stroke or systemic embolism was significantly lower in patients treated with NOACs (1.9%) compared with warfarin (3.7%) (odds ratio [OR] 0.43; 95% confidence interval [CI] 0.22-0.85; P = .02). Ischemic stroke (OR 0.72; 95% CI 0.18-2.93), hemorrhagic stroke (OR 0.18; 95% CI 0.03-1.05), cardiovascular death (OR 0.78; 95% CI 0.38-1.62), and all-cause mortality (OR 0.94; 95% CI 0.55-1.62) were not significantly different among groups. Major bleeding was significantly lower in patients treated with NOAC (2.8%) compared with warfarin (4.7%) (OR 0.49; 95% CI 0.28-0.88; P = .02).

      Conclusions

      In patients with atrial fibrillation and bioprosthetic valves or valve repair, NOACs are associated with a reduced incidence of thromboembolic events and major bleeding as compared with warfarin. Thus, NOACs may be considered a preferred option for this patient population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Eguchi K
        • Ohtaki E
        • Matsumura T
        • et al.
        Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation.
        Eur Heart J. 2005; 26: 1866-1872
        • Ngaage DL
        • Schaff HV
        • Barnes SA
        • et al.
        Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery?.
        Ann Thorac Surg. 2006; 82: 1392-1399
        • Otto CM
        • Nishimura RA
        • et al.
        • Writing Committee Members
        2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2021; 77: e25-e197
        • Hindricks G
        • Potpara T
        • Dagres N
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2021; 42: 373-498
        • Sun JC
        • Davidson MJ
        • Lamy A
        • Eikelboom JW.
        Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends.
        Lancet. 2009; 374: 565-576
        • Siontis KC
        • Yao X
        • Gersh BJ
        • Noseworthy PA.
        Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis.
        Circulation. 2017; 135: 714-716
        • Carnicelli AP
        • De Caterina R
        • Halperin JL
        • et al.
        Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves.
        Circulation. 2017; 135: 1273-1275
        • Avezum A
        • Lopes RD
        • Schulte PJ
        • et al.
        Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial.
        Circulation. 2015; 132: 624-632
        • Guimaraes HP
        • Lopes RD
        • de Barros ESPGM
        • et al.
        Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.
        N Engl J Med. 2020; 383: 2117-2126
        • Higgins JP
        • Altman DG
        • Gotzsche PC
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Moher D
        • Liberati A
        • Tetzlaff J
        • et al.
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Duraes AR
        • de Souza Roriz P
        • de Almeida Nunes B
        • et al.
        Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study.
        Drugs R D. 2016; 16: 149-154
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Guimaraes PO
        • Pokorney SD
        • Lopes RD
        • et al.
        Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial.
        Clin Cardiol. 2019; 42: 568-571
        • Giugliano RP
        • Ruff CT
        • Braunwald E
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • January CT
        • Wann LS
        • Calkins H
        • et al.
        2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
        Circulation. 2019; 140: e125-e151
      1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation .2021;143:e72-e227.

        • Ogawa H
        • An Y
        • Ishigami K
        • et al.
        Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: the Fushimi AF registry.
        Eur Heart J Qual Care Clin Outcomes. 2021; 7: 163-171
        • Bahit MC
        • Lopes RD
        • Wojdyla DM
        • et al.
        Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
        Heart. 2017; 103: 623-628
        • Agarwal S
        • Hachamovitch R
        • Menon V.
        Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
        Arch Intern Med. 2012; 172 (discussion 631-633): 623-631
        • Ruff CT
        • Giugliano RP
        • Braunwald E
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
        Lancet. 2014; 383: 955-962
        • Chan YH
        • See LC
        • Tu HT
        • et al.
        Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in asians with nonvalvular atrial fibrillation.
        J Am Heart Assoc. 2018; 7: e8150
        • Tsai CT
        • Liao JN
        • Chiang CE
        • et al.
        Association of ischemic stroke, major bleeding, and other adverse events with warfarin use vs non-vitamin k antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage.
        JAMA Netw Open. 2020; 3e206424
        • Malhotra K
        • Ishfaq MF
        • Goyal N
        • et al.
        Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis.
        Neurology. 2019; 92: e2421-e2431
      2. Grymonprez M, De Backer TL, Steurbaut S, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation and (morbid) obesity or low body weight: a systematic review and meta-analysis [e-pub ahead of print]. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-020-07122-6, Accessed September 15, 2021.

      3. Huang ZC, Li CQ, Liu XY, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review [e-pub ahead of print]. Cardiovasc Drugs Ther. doi: 10.1007/s10557-020-07065-y, accessed month day, year.

        • Massel DR
        • Little SH.
        Antiplatelet and anticoagulation for patients with prosthetic heart valves.
        Cochrane Database Syst Rev. 2013; CD003464
        • Lopes RD
        • Heizer G
        • Aronson R
        • et al.
        Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.
        N Engl J Med. 2019; 380: 1509-1524